The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis

被引:32
|
作者
Schweitzer, Nora [1 ]
Weber, Tim [1 ]
Kirstein, Martha M. [1 ]
Fischer, Mareike [1 ,2 ]
Kratzel, Anna-Maria [1 ]
Reineke-Plaass, Tanja [3 ]
Lehner, Frank [4 ]
Manns, Michael P. [1 ]
Vogel, Arndt [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Klinikum Hildesheim, Dept Cardiol Angiol & Intens Care, Senator Braun Allee 33, D-31135 Hildesheim, Germany
[3] Hannover Med Sch, Dept Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
[4] Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Cholangiocarcinoma; CCA; Intrahepatic; ICC; Survival; Adjuvant chemotherapy; PROGNOSTIC-FACTORS; SURGICAL-TREATMENT; MORTALITY-RATES; UNITED-STATES; TRENDS; SURVIVAL; BILIARY; EXPERIENCE; INCREASE; CANCER;
D O I
10.1007/s00432-017-2392-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to identify prognostic factors of patients with intrahepatic cholangiocarcinoma (ICC) treated with resection and to investigate the effect of adjuvant chemotherapy (CT). Patients with ICC diagnosed between 2000 and 2015 treated at Hannover Medical School were included. Clinicopathologic characteristics were analyzed in univariate and multivariate analysis. In a matched pair survival analysis, patients with or without adjuvant CT were matched by these prognostic factors. Two hundred and ten patients were included. Median survival was 28.7 months, 1-, 3-, and 5-year survival rates were 72.8%, 29.6%, and 14.1%, respectively. In multivariate analysis, lymph node involvement (p = 0.006, HR 1.84), larger tumor size (p = 0.013, HR 1.79), vascular invasion (p = 0.038, HR 1.70), and prolongation of prothrombin time (p < 0.001, HR 4.20) were significantly related to poor survival. Thirty-nine patients received adjuvant CT of which 60% had lymph node involvement. Each 25 patients with and without adjuvant CT were matched to the identified prognostic factors. The median survival of patients with adjuvant CT was 33.5 months, compared to 18 months in the control group (p = 0.002). The 1-, 3-, and 5-year survival rates were 96, 36, and 12%, compared to 60, 4, and 0% in non-treated patients. We identified several prognostic factors for patients with ICC treated with resection. Our data support the use of adjuvant CT in patients with ICC. The results of prospective randomized controlled studies will clarify the role of adjuvant CT in the future.
引用
收藏
页码:1347 / 1355
页数:9
相关论文
共 50 条
  • [31] Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery
    Park, Hyeong Min
    Yun, Sung Pil
    Lee, Eung Chang
    Lee, Seung Duk
    Han, Sung-Sik
    Kim, Seoung Hoon
    Park, Sang-Jae
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (13) : 4392 - 4400
  • [32] Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma
    Zhou, Xin-Da
    Tang, Zhao-You
    Fan, Jia
    Zhou, Jian
    Wu, Zhi-Quan
    Qin, Lun-Xiu
    Ma, Zeng-Chen
    Sun, Hui-Chuan
    Qiu, Shuang-Jian
    Yu, Yao
    Ren, Ning
    Ye, Qing-Hai
    Wang, Lu
    Ye, Sheng-Long
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (08) : 1073 - 1080
  • [33] Ablative Therapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis
    Yousaf, Ali
    Kim, Jin U.
    Eliahoo, Joseph
    Taylor-Robinson, Simon D.
    Khan, Shahid A.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (06) : 740 - 748
  • [34] Prognostic Risk Factors Associated with Recurrence and Metastasis After Radical Resection in Patients with Hepatolithiasis Complicated by Intrahepatic Cholangiocarcinoma
    Zhu, Yufei
    Zhu, Yunhai
    Cai, Feng
    Zhao, Jie
    Liu, Feng
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 73 (02) : 455 - 460
  • [35] Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis
    Rangarajan, Karan
    Simmons, George
    Manas, Derek
    Malik, Hasan
    Hamady, Zaed Z.
    EJSO, 2020, 46 (04): : 684 - 693
  • [36] Prognostic factors in patients with intrahepatic cholangiocarcinoma
    Chang, Yun-Jau
    Chang, Yao-Jen
    Chen, Li-Ju
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [37] The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma
    Morino, Koshiro
    Seo, Satoru
    Yoh, Tomoaki
    Nishino, Hiroto
    Yamanaka, Kenya
    Fukumitsu, Ken
    Ishii, Takamichi
    Taura, Kojiro
    Okajima, Hideaki
    Kaido, Toshimi
    Uemoto, Shinji
    ANTICANCER RESEARCH, 2019, 39 (04) : 2155 - 2161
  • [38] Analysis of Post-operative Adjuvant Chemotherapy Versus Adjuvant Chemoradiation Therapy Outcomes in Non-metastatic Cholangiocarcinoma: an NCDB Review
    Rodriguez, Robin R.
    Abel, Stephen
    Mamadgi, Jyothika
    Renz, Paul B.
    Wegner, Rodney E.
    Raj, Moses S.
    JOURNAL OF GASTROINTESTINAL CANCER, 2022, 53 (03) : 700 - 708
  • [39] The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis
    Ke, Qiao
    Lin, Nanping
    Deng, Manjun
    Wang, Lei
    Zeng, Yongyi
    Liu, Jingfeng
    PLOS ONE, 2020, 15 (02):
  • [40] Prognostic value of platelet to lymphocyte ratio in patients with intrahepatic cholangiocarcinoma
    Ramen, Kuvaneshan
    Zeng, Qiqiang
    Mo, Zhichao
    Shan, Yunfeng
    Zheng, Jie
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (06): : 5945 - 5952